Natco Pharma
Tracked across 7 events · 48 articles · First seen Mar 20, 2025 · Last active Aug 25, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Natco Pharma is the reporting company; its Q1 results show a significant profit decline due to lower lenalidomide sales, impacting its financial performance and market perception.
Aug 14, 2026 · 6 articles
Business
Impact: Natco Pharma is the investor, committing $14 million to eGenesis, increasing its total stake to $22 million. The investment aligns with its strategy to diversify into advanced therapeutics, though its stock fell 1.92% on the day.
Aug 25, 2026 · 6 articles
Business
Impact: Natco Pharma is a key player in launching generic semaglutide in India at a significantly lower price, aiming to capture a substantial share of the weight-loss drug market.
Mar 20, 2026 · 8 articles
Business
Impact: Natco Pharma, in alliance with Lupin (company), secured U.S. FDA approval for its Abbreviated New Drug Application for Eribulin Mesylate Injection, enhancing its oncology portfolio and market presence.
Jun 03, 2026 · 8 articles
Regulatory
Impact: NATCO will manufacture the generic Olaparib tablets. The tentative approval enhances its manufacturing portfolio and partnership with Alembic.
Jul 19, 2026 · 6 articles
Business
Impact: Natco Pharma is one of several Indian companies that launched generic versions of semaglutide, increasing competition for Novo Nordisk.
Mar 30, 2026 · 8 articles
Business
Impact: Natco Pharma continues to be an investor in Pee Safe.
Mar 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Natco Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard